Abstract library

9 results for "progesterone".
#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression
Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Prof Rachel Riechelmann
#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland
Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr.med. Alexander Siebenhüner
#2945 Misdiagnosis of Pancreatic Neuroendocrine Carcinoma - A Potential Threat
Introduction: Pancreatic neuroendocrine tumors (PNETs) are a rare clinical entity.Very less data is available in Pakistan on PNETs.Common metastatic sites are liver, lung and brain Reports involving metastasis to breast are almost negligible.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Doctor Azka Athar
Authors: Athar A, ...
#149 Giant adrenal tumor: a case report
Introduction: A gigantic adrenal tumor is a challenge regarding diagnosis before surgery and pathological exam, but also related to the surgical approach itself due to multiple risks.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Assoc. Professor Catalina Poiana
#175 The Immunohistochemical (IHC) Expression and Prognostic Value of ER, PR, and HER2/neu in Pancreatic and Small Intestinal Neuroendocrine Tumors
Introduction: There has been limited study of ER and PR expression in gastrointestinal neuroendocrine tumors (GINETs) and data on HER2/neu overexpression in GINETS has been conflicting.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Daniel Rayson
#240 Glycodelin Expression in Pancreatic Neuroendocrine and Solid-Pseudopapillary Tumors as in Important Factor of Favorable Disease Prognosis
Introduction: Glycodelin (GD) is a multifunctional highly glycosylated protein, expressed in hormone-dependent human tissues and tumors. GD participates in apoptosis regulation and inter-cellular adhesion.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Larissa Gurevich
#1544 Immunohistochemical Expression of Estrogen and Progesterone Receptors in Neuroendocrine Tumors
Introduction: Expression of progesterone (PR) and estrogen receptor (ER) in some neuroendocrine tumors (NET) raises the possibility of hormonal regulation in these tumors, but those prevalence and clinical implication are unknown.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Daniela Lacerda Costa
#1592 Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Approach to the Special Type of Breast Malignancy
Introduction: WHO classification from 2003 defines primary neuroendocrine carcinomas (NEC) of the breast as a group of tumors with expression of neuroendocrine markers in more than 50% of tumor cells. In the current WHO classification this category is renamed to “carcinomas with neuroendocrine features” without defined clear-cut of the percentage of tumor cells positive for neuroendocrine markers.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Alma Demirović
#2155 Menstrual Dysfunction in Women with Prolactinomas
Introduction: Hyperprolactinemia syndrome (HPS) is a set of symptoms with typical increase in serum prolactin accompanied by galactorrhea, hypogonadism and potential infertility
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Student Mijgona Safarova